MediBeacon has hired James M. Harr, a former Global Vice President of R&D at Medtronic
ST. LOUIS, February 13, 2020 – MediBeacon Inc. announced today that they have hired James M. Harr in the role of Vice President, Research and Development.
Jim has spent the last 25 years developing world class medical products. Over the last 19 years he held various leadership roles at Covidien, Medtronic and Cardinal Health. Jim was the Global Vice President of Research & Development from 2013-2017 for Covidien/Medtronic/Cardinal Health responsible for $4.5 billion dollar medical supply business. Jim is a certified DFSS (Design for Six Sigma) Blackbelt and was awarded numerous company-wide awards for both design and leadership excellence.
Jim has 45 patents to his name and was a vital contributor to the culture of innovation at Covidien. During his tenure at the Covidien family of companies, the division globally launched four new infusion pump platforms, three new thermometer platforms (fast predictive and tympanic), two new imaging devices and countless new disposables platforms across the portfolio. From 2018 to 2019 Jim worked as a new product development consultant with Olympus Surgical Technologies.
Jim will lead all of MediBeacon’s R & D activities including the continued development of the Transdermal GFR Measurement System (TGFR) program which is poised to begin its Pivotal trial in the U.S. and Europe. The TGFR is designed to measure kidney function at the point of care without the need for blood sampling or urine collection. The U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the TGFR in 2018. MediBeacon’s agents and devices are not approved for human use by any regulatory agency.
The MediBeacon research and development focus includes additional applications of the Company’s fluorescent tracer agent-based measurement and monitoring systems in Gastroenterology, Ophthalmology and beyond.
About MediBeacon Inc..
MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. The company has conducted numerous clinical studies focused on the transdermal detection of novel fluorescent agents as a means to measure physiological function. The U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the Company’s Transdermal GFR Measurement System (TGFR). Focus is on solutions that could potentially change the standard of care in numerous clinical situations with a view to delivering measurable differences in global health.
Learn more about MediBeacon at www.medibeacon.com.
1 Data on file. MediBeacon Inc., St. Louis, MO.
# # #